ArticleHolistic integrative oncology.2022
CACA Guidelines for Holistic Integrative Management of Breast Cancer.
Open access · diamondAbstract read
In one paragraph
Article in Holistic integrative oncology., 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Intraperitoneal chemotherapy for gastric cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial.BMC medicine · 2026Trial
- Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.Scientific reports · 2024Trial
- Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases.Asian journal of andrology · 2026Article
- Multiscale Spatial Fusion Feature-Driven Characterization of Gastric Cancer Invasive Margins: A Multicenter Cohort Study for Preoperative Accurate Differentiation Between T4a and T4b Subtypes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer.Cancer research · 2026Article
- Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.Nature communications · 2026Article
- Hallmarks of lung cancer driven by inhalable particulate matter: From cell-intrinsic oncogenic traits to microenvironment remodeling.Innovation (Cambridge (Mass.)) · 2026Review
- Burden profiles and mortality-attributable risk factors for gastrointestinal cancers: A comprehensive analysis, 1990-2021.Journal of advanced research · 2026Article
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Comparison of neoadjuvant TCbHP versus THP in HER2-positive breast cancer: a retrospective cohort study.Gland surgery · 2026Article
- Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.Signal transduction and targeted therapy · 2026Article
- Survey of the Senologic International Society (SIS) on the Use of Preoperative Breast MRI in Early-Stage Breast Cancer: A Global Perspective on Current Practice.European journal of breast health · 2026Article
- Prolonged S-adenosylmethionine exposure is associated with poorer treatment response and adverse outcomes in breast cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter study.Journal of translational internal medicine · 2026Article
- A non-invasive end-to-end intelligent assistance system for breast ultrasound.Nature communications · 2026Article
- Article
- Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.BMC women's health · 2026Article
- Comprehensive analysis of learning curve and surgical outcomes of endoscopic thyroidectomy for papillary thyroid carcinoma: a prospective study.Langenbeck's archives of surgery · 2026Article
- The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990-2021: Results From the Global Burden of Disease Study 2021.Cancer innovation · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors at 20 institutions in 2 countries.
Jiong WuKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Daiming FanDepartment of Gastroenterology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Zhimin ShaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Binghe XuNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Guosheng RenDepartment of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing China.
Zefei JiangMedicine-Oncology, The Affiliated Hospital of Military Medical Sciences (The 307th Hospital of Chinese People's Liberation Army), Beijing, China.
Yongsheng WangBreast Disease Center, Shandong Cancer Hospital, Jinan, China.
Feng JinDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jin ZhangThe 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, China.
Qingyuan ZhangHarbin Medical University Cancer Hospital, Harbin, China.
Fei MaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jinli MaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Zhonghua WangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Shusen WangSun Yat-Sen University Cancer Center, Guangzhou, China.
Xiaojia WangZhejiang Cancer Hospital, Hangzhou, China.
Shu WangBreast Center, Peking University People's Hospital, Beijing, China.
Haibo WangDepartment of Breast Center, The Affiliated Hospital of Qingdao University, Shandong, China.
Tao WangDepartment of Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiang WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jia WangDepartment of Breast Surgery, Institute of Breast Disease, The Second Hospital of Dalian Medical University, Dalian, Liaoning China.
Biyun WangDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Li FuDepartment of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Hongyuan LiDepartment of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
Yehui ShiKey Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.
Lu GanDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yunjiang LiuBreast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jian LiuDepartment of Breast Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang China.
Zhenzhen LiuDepartment of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Qiang LiuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Qiang SunDepartment of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Wenwu ChengDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Keda YuKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Zhongsheng TongDepartment of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xinhong WuHubei Provincial Clinical Research Center for Breast Cancer, Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chuangui SongDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Jianguo ZhangDepartment of Breast Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang China.
Jian ZhangDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Junjie LiKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Bin LiKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Man LiThe Second Affiliated Hospital of Dalian Medical University; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Huiping LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Wentao YangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongjian YangDepartment of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang China.
Benlong YangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Hong BuLaboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, China.
Juping ShenKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Zhenzhou ShenKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Yiding ChenDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ceshi ChenKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Da PangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Zhimin FanDepartment of Breast Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin China.
Ying ZhengDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Xiaoli YuDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Guangyu LiuKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Xichun HuDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Yiqun LingDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Jinhai TangDepartment of Breast Cancer, Jiangsu Province Hospital, Nanjing, China.
Yongmei YinDepartment of Breast Cancer, Jiangsu Province Hospital, Nanjing, China.
Cuizhi GengDepartment of Breast Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Peng YuanNational Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yajia GuDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Cai ChangDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Xuchen CaoKey Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.
Yuan ShengDepartment of Breast Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Yuanxi HuangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Jian HuangDepartment of Breast Surgery, Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Cancer Research Institute of Zhejiang University, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China.
Weijun PengDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Xiaohua ZengBreast Center, Chongqing Cancer Hospital, Chongqing University, Chongqing, China.
Yuntao XieKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Ning LiaoDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong China.
Committee of Breast Cancer Society, Chinese Anti-Cancer Association
Shanghai Medical College of Fudan University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHarbin Medical University · CNFudan University Shanghai Cancer Center · CNHebei Medical University · CNTianjin Medical University Cancer Institute and Hospital · CNPeking University · CNSun Yat-sen University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNDalian Medical University · CN307th Hospital of Chinese People’s Liberation Army · CNChina Medical University · CNChongqing University · CNFujian Medical University · CNQingdao University · CNShandong Tumor Hospital · CNZhejiang University · CNJiangsu Cancer Hospital · CNSecond Military Medical University · CNSichuan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer is now the most common malignant tumor worldwide. About one-fourth of female cancer patients all over the world suffer from breast cancer. And about one in six female cancer deaths worldwide is caused by breast cancer. In terms of absolute numbers of cases and deaths, China ranks first in the world. The CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in China. Methods: The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to classify evidence and consensus. Results: The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer, breast cancer screening, breast cancer diagnosis, early breast cancer treatment, advanced breast cancer treatment, follow-up, rehabilitation, and traditional Chinese medicine treatment of breast cancer patients. Conclusion: We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines.
Indexed as
Advanced breast cancer treatmentBreast cancer diagnosisBreast cancer screeningEarly breast cancer treatmentEpidemiology of breast cancerTraditional Chinese medicine treatment of breast cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.